Assessment of Bronchial Asthma Among Patients Attending Sohag University Hospital

Last updated: November 15, 2023
Sponsor: Sohag University
Overall Status: Active - Recruiting

Phase

N/A

Condition

Allergies & Asthma

Asthma

Treatment

corticosteroids

Clinical Study ID

NCT06141161
Soh-Med-23-10-015MS
  • Ages > 18
  • All Genders

Study Summary

Asthma is a significant public health threat, affecting more than 300 million individuals globally. Asthma is classified as a non-communicable disease and leads to reduced quality of life, poor physical functioning and reduced emotional well-being. The impact of this disease can be widespread and extends beyond the person living with the disease, affecting the lives of their family members, carers, communities and the health care system (1).

Asthma is a variable chronic respiratory condition. It is characterized by symptoms of wheeze, cough, chest tightness, dyspnea and backed by variable airflow limitation, airway inflammation and airway hyper-responsiveness (AHR). The severity of asthma varies considerably, both between individuals and within individuals over time. Some people may have intermittent asthma and others may experience severe, potentially life-threatening disease (2, 3,4).

Eligibility Criteria

Inclusion

Inclusion Criteria:

  • bronchial asthma patients aged more than 18 years, both sexes are included

Exclusion

Exclusion Criteria:

  • children ,patients who are unable to do spiromerty or contrindecated

Study Design

Total Participants: 200
Treatment Group(s): 1
Primary Treatment: corticosteroids
Phase:
Study Start date:
November 01, 2023
Estimated Completion Date:
December 30, 2024

Connect with a study center

  • Sohag University hospitals

    Sohag,
    Egypt

    Active - Recruiting

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.